Updated MDNA11 Clinical Trial Results in Advanced Solid Tumors Presented
“The most important message from today’s data is that they absolutely add to the differentiation of MDNA11’s mechanism relative to other next-generation IL-2s and reinforce the consistency of its anti-tumor activity in late stage cancers refractory to checkpoint inhibitors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “With durable responses in multiple late stage metastatic tumors, including pancreatic, breast, colorectal, endometrial, bladder, anal cancer and melanoma, it is difficult for us not to conclude that MDNA11 demonstrates meaningful efficacy. The recent announcement of the NEO-CYT trial sponsored by Fondazione Melanoma, in pre-surgery patients with high-risk melanoma, provides external validation of our approach and adds to our conviction that MDNA11 is potentially a de-risked drug candidate for earlier stage cancer patients harbouring healthier immune systems. We look forward to sharing new and mature data in the coming weeks and months from the ABILITY-1 study, new data from the NEO-CYT study and non-human primate data with MDNA113, our targeted and conditionally activated anti-PD1-IL-2 BiSKIT which is anticipated to enter its first in human study later next year.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a